Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | TAR DNA binding protein | Starlite/ChEMBL | No references |
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Homo sapiens | glycoprotein hormones, alpha polypeptide | Starlite/ChEMBL | No references |
Homo sapiens | nuclear factor, erythroid 2-like 2 | Starlite/ChEMBL | No references |
Homo sapiens | APEX nuclease (multifunctional DNA repair enzyme) 1 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Toxoplasma gondii | intraflagellar transport protein 172, putative | glycoprotein hormones, alpha polypeptide | 116 aa | 94 aa | 26.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | conserved hypothetical protein | 0.0034 | 0.2146 | 1 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0043 | 0.3855 | 0.3855 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0025 | 0.0369 | 0.1719 |
Plasmodium falciparum | basic transcription factor 3b, putative | 0.0034 | 0.2146 | 1 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.006 | 0.697 | 0.697 |
Echinococcus multilocularis | transcription factor btf3 | 0.0034 | 0.2146 | 0.2146 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.006 | 0.697 | 0.697 |
Entamoeba histolytica | transcription factor BTF3, putative | 0.0034 | 0.2146 | 0.5567 |
Giardia lamblia | Endonuclease/Exonuclease/phosphatase | 0.0023 | 0 | 0.5 |
Echinococcus multilocularis | tar DNA binding protein | 0.0076 | 1 | 1 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.0023 | 0 | 0.5 |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0043 | 0.3855 | 0.3855 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.0025 | 0.0369 | 0.1719 |
Mycobacterium ulcerans | exodeoxyribonuclease III protein XthA | 0.0023 | 0 | 0.5 |
Trypanosoma brucei | transcription factor BTF3, putative | 0.0034 | 0.2146 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Echinococcus granulosus | tar DNA binding protein | 0.0076 | 1 | 1 |
Loa Loa (eye worm) | ICD-1 protein | 0.0034 | 0.2146 | 0.2146 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0076 | 1 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.3855 | 1 |
Loa Loa (eye worm) | RNA binding protein | 0.0076 | 1 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0034 | 0.2146 | 1 |
Echinococcus granulosus | transcription factor btf3 | 0.0034 | 0.2146 | 0.2146 |
Plasmodium vivax | basic transcription factor 3b, putative | 0.0034 | 0.2146 | 1 |
Trypanosoma cruzi | transcription factor btf3, putative | 0.0034 | 0.2146 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0041 | 0.3429 | 0.3429 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0043 | 0.3855 | 0.3855 |
Schistosoma mansoni | hypothetical protein | 0.0043 | 0.3855 | 0.3855 |
Leishmania major | hypothetical protein, conserved | 0.0025 | 0.0369 | 0.1719 |
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.0023 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0025 | 0.0369 | 0.0369 |
Trypanosoma cruzi | transcription factor btf3, putative | 0.0034 | 0.2146 | 1 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.0025 | 0.0369 | 0.1719 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0034 | 0.2146 | 0.5567 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.006 | 0.697 | 0.697 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.0025 | 0.0369 | 0.1719 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.3855 | 1 |
Leishmania major | basic transcription factor 3a, putative | 0.0034 | 0.2146 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.3855 | 1 |
Toxoplasma gondii | NAC domain-containing protein | 0.0034 | 0.2146 | 1 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0025 | 0.0369 | 0.1719 |
Brugia malayi | hypothetical protein | 0.0043 | 0.3855 | 0.3855 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.3855 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0041 | 0.3429 | 0.3429 |
Brugia malayi | beta-NAC-like protein | 0.0034 | 0.2146 | 0.2146 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0041 | 0.3429 | 0.3429 |
Loa Loa (eye worm) | TAR-binding protein | 0.0076 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 0.697 | 0.697 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Mycobacterium tuberculosis | Probable exodeoxyribonuclease III protein XthA (exonuclease III) (EXO III) (AP endonuclease VI) | 0.0023 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Brugia malayi | hypothetical protein | 0.0025 | 0.0369 | 0.0369 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0076 | 1 | 1 |
Schistosoma mansoni | transcription factor btf3 | 0.0034 | 0.2146 | 0.2146 |
Brugia malayi | TAR-binding protein | 0.0076 | 1 | 1 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0025 | 0.0369 | 0.1719 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0034 | 0.2146 | 1 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0025 | 0.0369 | 0.1719 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (functional) | > 53 uM | PUBCHEM_BIOASSAY: Dose Response confirmation of uHTS hits for small molecule agonists of the CRF-binding protein and CRF-R2 receptor complex. (Class of assay: confirmatory) | ChEMBL. | No reference |
IC50 (functional) | > 47.1 uM | PUBCHEM_BIOASSAY: Dose Response confirmation of uHTS hits for small molecule antagonists of the CRF-binding protein and CRF-R2 receptor complex. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 0.5221 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 2.5119 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 3.5481 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 7.0795 uM | PubChem BioAssay. qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 12.5893 uM | PubChem BioAssay. qHTS of Nrf2 Activators. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 12.5893 uM | PubChem BioAssay. qHTS for Activators of Integrin-Mediated Alleviation for Muscular Dystrophy. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS Assay for Agonists of the Relaxin Receptor RXFP1. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 89.1251 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase). (Class of assay: confirmatory) | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.